Research Paper Volume 12, Issue 1 pp 462—480

Figure 3. The RNA or protein expression changes of lung cancer cells with lnc-BMPl-1 over-expression vs. NC cells, the CSE vs. DMSO treated 16HBE cells, and 5-AzaC or TSA treatment. (A) The protein expression of Bcl-2, Cav-1 and DNMT3a in different lung cancer cell lines with lnc-BMP1-1 over-expression vs. NC cells; the protein expression were detected using western blotting analyses, protein expression was normalized against GAPDH or α-tubulin protein; the value above each band indicates the fold change of protein expression relative to their control; (B) The cell viability of CSE (vs. DMSO) treated 16HBE cells at 5^th passage; (C) The cell viability of CSE (vs. DMSO) treated 16HBE cells at 10^th passage; (D) The expression of lnc-BMP1-1, Cav-1 were reduced in CSE treated 16HBE cells both in 5^th and 10^th passage, and made greater decline in 10^th than in 5^th passage (the same gene was compared in 5^th and 10^th generation of CSE treated 16HBE cells, #P<0.05, ##P<0.01). The mRNA expression of Cav-1 in A549-BMP vs. A549-NC (E), GLC82-BMP vs. GLC82-NC(F), respectively; In A549 cells treated with TSA, the expression of lnc-BMP1-1 (G) and Cav-7 (H) were increased, while DNMT3a (I) was decreased; The protein expression of HDAC2 (J) was decreased in A549-BMP cells. Data are represented as means ± SD. *P< 0.05, **P<0.01.